Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.

Morse MA.

Curr Opin Mol Ther. 2005 Dec;7(6):588-97.

PMID:
16370382
2.

Entecavir (Bristol-Myers Squibb).

Billich A.

Curr Opin Investig Drugs. 2001 May;2(5):617-21. Review.

PMID:
11569933
3.

BMS-561392. Bristol-Myers Squibb.

Grootveld M, McDermott MF.

Curr Opin Investig Drugs. 2003 May;4(5):598-602. Review.

PMID:
12833656
4.

Cetuximab (Imclone/Merck/Bristol-Myers Squibb).

Kies MS, Harari PM.

Curr Opin Investig Drugs. 2002 Jul;3(7):1092-100. Review.

PMID:
12186273
5.

Case study: technology initiative led to advanced lead optimization screening processes at Bristol-Myers Squibb, 2004-2009.

Zhang L, Cvijic ME, Lippy J, Myslik J, Brenner SL, Binnie A, Houston JG.

Drug Discov Today. 2012 Jul;17(13-14):733-40. doi: 10.1016/j.drudis.2012.02.012. Epub 2012 Mar 7. Review.

PMID:
22425710
6.

Anti-MRSA cephalosporins Bristol-Myers Squibb.

Johnson AP.

Curr Opin Investig Drugs. 2001 Feb;2(2):205-8. Review.

PMID:
11816831
7.

BMS-275291. Bristol-Myers Squibb.

Poulaki V.

Curr Opin Investig Drugs. 2002 Mar;3(3):500-4. Review.

PMID:
12054103
8.

Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006.

Houston JG, Banks MN, Binnie A, Brenner S, O'Connell J, Petrillo EW.

Drug Discov Today. 2008 Jan;13(1-2):44-51. doi: 10.1016/j.drudis.2007.11.004. Epub 2008 Jan 3. Review.

PMID:
18190863
9.

Omapatrilat. Bristol-Myers Squibb.

Tabrizchi R.

Curr Opin Investig Drugs. 2001 Oct;2(10):1414-22. Review.

PMID:
11890357
10.

Deal watch: Bristol-Myers Squibb invests in cancer antibody that targets the innate immune system.

[No authors listed]

Nat Rev Drug Discov. 2011 Aug 31;10(9):648. doi: 10.1038/nrd3537. No abstract available.

PMID:
21878969
11.

Technology evaluation: abatacept, Bristol-Myers Squibb.

Dumont FJ.

Curr Opin Mol Ther. 2004 Jun;6(3):318-30. Review.

PMID:
15264435
12.

HIV/AIDS in African children: the Bristol-Myers Squibb Foundation and Baylor response.

Damonti J, Doykos P, Wanless RS, Kline M.

Health Aff (Millwood). 2012 Jul;31(7):1636-42. doi: 10.1377/hlthaff.2012.0425.

PMID:
22778353
13.

BMS-193884 and BMS-207940 Bristol-Myers Squibb.

Hulpke-Wette M, Buchhorn R.

Curr Opin Investig Drugs. 2002 Jul;3(7):1057-61. Review.

PMID:
12186267
15.

BMS-310705 Bristol-Myers Squibb/GBF.

Kolman A.

Curr Opin Investig Drugs. 2004 Dec;5(12):1292-7. Review.

PMID:
15648951
16.

BMS-204352 (Bristol Myers Squibb).

Mackay KB.

Curr Opin Investig Drugs. 2001 Jun;2(6):820-3. Review.

PMID:
11572663
17.

BMS-232632 (Novartis/Bristol-Myers Squibb).

Witherell G.

Curr Opin Investig Drugs. 2001 Mar;2(3):340-7.

PMID:
11575702
19.

DPC-423 Bristol-Myers Squibb.

Taglialatela M.

Curr Opin Investig Drugs. 2002 Feb;3(2):252-4. Review.

PMID:
12020055
20.

Ravuconazole Eisai/Bristol-Myers Squibb.

Arikan S, Rex JH.

Curr Opin Investig Drugs. 2002 Apr;3(4):555-61. Review.

PMID:
12090723
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk